TScan Therapeutics, Inc.
NASDAQ:TCRXBiotechnology
+$0.02 today
- Market cap
- $50.37M
- Beta
- 1.03
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.96
Volume 0.00M
Average 0.81M
Returns on capital
TScan Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-105.4%
avg -40.7%
ROIC
-62.5%
avg -44.6%
ROA
-56.7%
avg -37.6%
Analysis
ROA is currently the strongest return metric at -56.7% versus its period average of -37.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Gavin MacBeath | Chief Executive Officer & Director | USD 818.65K | 56 | 1.17M | 1.91% |
Zoran Zdraveski | Chief Legal & Strategy Officer and Company Secretary | USD 657.2K | 56 | 350.00K | 0.57% |
Chrystal U. Louis | Chief Medical Officer | USD 618.2K | 50 | — | — |
Jason A. Amello | CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer | USD 606.8K | 58 | — | — |
Shrikanta Chattopadhyay | Senior Vice President & Head of Translational Medicine | — | — | — | — |
Stephen J. Elledge | Co-Founder & Chairman of Scientific Advisory Board | — | — | — | — |
Cagan Gurer | Senior Vice President of Discovery | — | — | — | — |
Jim Murray | Chief Development Operations Officer | — | — | — | — |
Stephen Camiolo | Senior Vice President of Market Access | — | — | — | — |
Tomasz Kula | Co-Founder & Member of Advisory Board | — | — | — | — |
Ann Hargraves | Chief Human Resources Officer | — | — | — | — |
Ray Lockard | Chief Manufacturing & Quality Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Jun 18, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 20, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$145,525.97
Sells
0
$0.00
Net Transaction Value
+$145,525.97
Net buying
Most Active
Lynx1 Capital Management LP
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Dec 23, 25Dec 23, 2025 | Lynx1 Capital Management LP Indirect | Buy | $5.6K$5,601.94 |
| Dec 22, 25Dec 22, 2025 | Lynx1 Capital Management LP Indirect | Buy | $68K$67,950.00 |
| Dec 19, 25Dec 19, 2025 | Lynx1 Capital Management LP Indirect | Buy | $72K$71,974.02 |
Summary
Insiders reported 3 buys worth $145,525.97 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $145,525.97. Lynx1 Capital Management LP was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -8.6% | +53.0% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -8.6% over three years. Forward estimates point to Revenue at +53.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does TScan Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about TCRX's management, answered from reported figures.
Who manages TCRX?
TScan Therapeutics, Inc. (TCRX) lists 12 active executives. The top listed executive is Gavin MacBeath, Chief Executive Officer & Director.
Are TCRX insiders buying or selling?
Recent insider activity shows net buying of $58.18M.
Continue the stock analysis
Jump to another research area for this company.